Clinical trial
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
NCT03125200 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
- Lead sponsor
- ADC Therapeutics S.A.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 18, 2017
- Completion date
- April 5, 2018
- Enrollment
- 21 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
bladder cancer, breast cancer, gastroesophageal cancer, non small cell lung cancer